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Abstract 25 
The Glasgow s17 syn+ strain of herpes simplex virus 1 (HSV1) is arguably the best 26 
characterised strain and has provided the reference sequence for HSV1 genetic 27 
studies. Here we show that our original s17 syn+ stock was a mixed population from 28 
which we have isolated a minor variant that, unlike other strains in the laboratory, fails 29 
to be efficiently released from infected cells and spreads predominantly by direct cell-30 
to-cell transmission. Analysis of other s17-derived viruses that had been isolated 31 
elsewhere revealed a number with the same release phenotype. Second generation 32 
sequencing of eight plaque-purified s17-derived viruses revealed sequences that vary 33 
by 50 SNPs including approximately 10 coding SNPs. This compared to interstrain 34 
variations of around 800 SNPs in strain Sc16, of which a quarter were coding 35 
changes. Amongst the variations found within s17, we identified thirteen variants of 36 
glycoprotein C within the original stock of virus which were predominantly a 37 
consequence of altered homopolymeric runs of C residues. Characterisation of seven 38 
isolates coding for different forms of gC indicated that all were expressed, despite six 39 
of them lacking a transmembrane domain. While the release phenotype did not 40 
correlate directly with any of these identified gC variations, further demonstration that 41 
nine clinical isolates of HSV1 also fail to spread through extracellular release raises 42 
the possibility that propagation in tissue culture had altered the HSV1 s17 43 
transmission phenotype. Hence, this s17 intrastrain variation identified here offers an 44 
excellent model for understanding both HSV1 transmission and tissue culture 45 
adaptation.   46 
  47 
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Introduction 49 
Herpes simplex virus 1 (HSV1) infects human mucosal epithelia before establishing 50 
lifelong latent infection in sensory neurons [1]. In a proportion of individuals, the virus 51 
reactivates periodically to cause recurrent cold sores, genital herpes or other rarer but 52 
more serious outcomes including encephalitis and keratitis [2, 3]. As such, the virus 53 
has the potential to undergo genetic change within an individual host through 54 
sequential episodes of reactivation, or when transmitted from one individual to 55 
another.  56 
HSV1 is a large enveloped virus with a 152 kb double-stranded DNA genome coding 57 
for at least 75 proteins, which are involved either directly in virus replication, such as 58 
for DNA replication or virus assembly, or indirectly in replication through immune 59 
evasion [4]. Single or combined genetic changes in these coding regions could dictate 60 
variations in the virulence of virus circulating in the human population. The HSV1 61 
genome was first fully sequenced in 1988 when the McGeoch laboratory produced the 62 
sequence of the Glasgow strain 17 syn+ virus by extensive DNA fragment cloning and 63 
Sanger sequencing [5]. However, it has taken until the last decade and the advent of 64 
second generation sequencing for other laboratory strains to be sequenced in full, 65 
including KOS [6, 7], McKrae [8] and F [9] allowing sequence comparison between 66 
strains that have been propagated in different laboratories. Fewer than 1% single 67 
nucleotide polymorphisms (SNPs) have been found between each of these strains 68 
and the strain 17 reference sequence, and these are spread across a large number of 69 
the 75 virus genes. Roughly one third of SNPs have been seen to be non-70 
synonymous. A smaller number of insertions/deletions (indels) have also been 71 
identified in these genomes in comparison to the reference genome, providing scope 72 
for a greater degree of divergence. More recently, sequencing of clinical samples of 73 
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HSV1 isolated from individuals from a range of global locations, has become a focus 74 
of attention for determining the evolution and diversity of HSV1 in the human 75 
population [10, 11]. In those studies, specific groups of genes have been determined 76 
to be conserved or divergent based on their variability across tens of sequenced 77 
genomes, with the highest diversity occuring in a number of envelope glycoproteins 78 
[10]. Many viruses were also found to exhibit frameshifts at homopolymeric runs as a 79 
result of variation in the length of these sequences [10], extending previous studies 80 
that revealed homopolymeric frameshifts in the glycoprotein G (gG) gene of a number 81 
of HSV1 and HSV2 clinical isolates [12, 13]. 82 
The likelihood of virus adaptation to cell culture may confound the interpretation of 83 
sequence differences between clinical and laboratory grown viruses. There is no 84 
better example of this than the rapid loss of a large part of the human cytomegalovirus 85 
(hCMV) genome over as few as three passages in cultured fibroblasts, resulting in 86 
virus that is less cell-associated and reduced in pathogenicity [14]. It is therefore not 87 
always clear if specific virus characteristics in culture are relevant to infection in the 88 
host.  Many of the commonly utilized laboratory strains of HSV1 were isolated 89 
decades ago and have been openly distributed to research laboratories. The Glasgow 90 
strain 17 syn+ is no exception – originally isolated in 1972 [15], many researchers 91 
throughout the world now use it as their prototype virus. By definition however, the 92 
strains in use today have an incomplete provenance, as most laboratory strains have 93 
been routinely grown in cells of non-human origin - particularly Vero and BHK cells for 94 
historical reasons of ease - for an unknown number of passages, and it is possible 95 
that genetic adaptation has taken place to such tissue culture conditions. A recent 96 
analysis of the KOS strain of HSV1 has looked at the effect of long-term tissue culture 97 
passage on that virus and surprisingly found only five coding changes between an 98 
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early and recent passage of the virus from the same laboratory [7], while a second 99 
study revealed 17 coding changes across three plaque-purified KOS viruses [16]. 100 
These studies suggest that HSV1 is relatively stable in culture. 101 
In our laboratory we have routinely used the original Glasgow strain 17 syn+ of HSV1 102 
as both our representative wild-type virus, and the parent virus for production of many 103 
recombinant viruses we have generated over the years. Early in our work we took the 104 
decision to plaque-purify this virus to take forward as our wild-type into our studies. 105 
Here, we show that our plaque purification inadvertently isolated a minor phenotypic 106 
variant of Glasgow strain 17 syn+ which has the same plaque morphology as other 107 
viruses that were subsequently plaque purified from strain 17 syn+ but has a defective 108 
release phenotype compared to the original stock of the virus and laboratory strains 109 
Sc16 [17] and KOS. This results in a virus that spreads predominantly cell-to-cell in 110 
culture rather than through extracellular release, a phenotype we have now identified 111 
in several other strain 17 syn+ derived viruses, most notably the transgenic strain 17 112 
Bac virus. Moreover, sequencing of the viral genome has shown the original Glasgow 113 
strain 17 syn+ stock to be a genetically heterogeneous mix of viruses, exemplified by 114 
a range of at least 13 glycoprotein C variants including eight frameshift variants. While 115 
these gC frameshift variants do not correlate with the identified defective spread 116 
phenotype, the further demonstration that nine newly isolated clinical HSV1 viruses 117 
were transmitted predominantly by cell-to-cell spread in culture indicates that our 118 
laboratory-adapted strains have undergone not only genotypic changes, but 119 
phenotypic changes that alter their behaviour in comparison to virus that has been 120 
isolated directly from the host. This provides new scope for exploring clinical aspects 121 
of HSV1 infection.  122 
  123 
	 6	
Materials and Methods 124 
Cells and Viruses. Vero cells were cultured in DMEM supplemented with 10% 125 
newborn calf serum. BSc1, SKOV3 and HCT116 cells were grown in DMEM media 126 
supplemented with 10% foetal bovine serum. Wild-type HSV1 Glasgow strain 17  syn+ 127 
was kindly provided by Roger Everett, University of Glasgow [15]. Our laboratory 128 
strain 17 was subsequently plaque-purified from the original stock of Glasgow strain 129 
17 syn+. Our D22 virus [18] is a derivative of the original Glasgow strain 17 syn+ virus, 130 
as are the DUL13 [19], DUL41 [20], and DICP0 [21] viruses that were kindly provided 131 
by Duncan McGeoch and Roger Everett, University of Glasgow. Transgenic strain 17 132 
(GenBank FJ593289.1) was kindly provided by Andrew Davison, University of 133 
Glasgow. Wild-type HSV1 strains Sc16 [17] and KOS [22] were kindly provided by 134 
Helena Browne, University of Cambridge and Peter O’Hare, Imperial College London, 135 
respectively.  All laboratory viruses were routinely propagated and titrated on Vero 136 
cells. Clinical variants of HSV1 provided by Mark Atkins, Frimley Park Hospital, were 137 
taken as swabs of genital lesions, stored in virus transport medium, and typed on the 138 
same day using a real-time PCR commercial kit from Pro Genie Molecular run on a 139 
Cepheid Smart Cycler using the manufacturer’s cycle conditions. The clinical isolates 140 
used in this study were plated out directly using a 1:4 dilution series to determine their 141 
plaque morphology without prior propagation in tissue culture.   142 
Virus Spread Assays. Cells grown in six-well plates were infected with approximately 143 
10 to 30 plaque-forming units of virus as determined by titration on Vero cells. 144 
Following adsorption for 1 hr, the inoculum was removed and replaced with medium 145 
with or without 1% pooled human serum (Seralab). Cells were incubated at 37°C 146 
without movement, to ensure only passive transmission of virus through liquid, and at 147 
the denoted times removed from the incubator to be fixed and stained with crystal 148 
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violet for plaque analysis, or to harvest extracellular virus to determine the amount of 149 
virus released. 150 
Illumina Sequencing. Short-read Illumina sequencing was carried out as has been 151 
described previously [23]. Sequence datasets were parsed through QUASR [24] and 152 
aligned against the s17 reference sequence (GenBank JN555585.1) using BWA [25]. 153 
The aligned read data were processed using SAMTools [26] and consensus 154 
sequences generated. SNP and indel differences between consensus sequences and 155 
the s17 reference sequence were determined using BaseByBase 156 
(http://athena.bioc.uvic.ca/) [27]. 157 
SDS-PAGE and Western blotting. Protein samples were analysed on 13% 158 
polyacrylamide gels and subjected to electrophoresis in Tris-glycine buffer. Gels were 159 
transferred to nitrocellulose membrane for Western blot analysis. Western blots were 160 
developed using SuperSignal West Pico chemiluminescent substrate (Thermo Fisher 161 
Scientific).  162 
Antibodies. Monoclonal anti-VP16 was kindly provided by Colin Crump, University of 163 
Cambridge; monoclonal anti-gC and anti-a tubulin were purchased from AbCam and 164 
Sigma respectively. 165 
PCR amplification, cloning and sequencing of gC. Virus genomic DNA was 166 
extracted from infected cells using a final concentration of 0.5% SDS and 10 mM 167 
EDTA, followed by two phenol-chloroform extractions and ethanol precipitation. The 168 
gC encoding gene UL44 was amplified by PCR using primers: (5’ 169 
GGATCCAGGCGTCGGGCATGGCC3’) and 170 
(5’CTCGAGTTACCGCCGATGACGCTGC 3’) 171 
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and cloned into the pCR-Blunt-II-TOPO vector (Invitrogen) for downstream 172 
sequencing. DNA from plaque purified Glasgow strain 17syn+ viruses was treated in 173 
the same way but PCR products were gel purified and sequenced directly. UL25 and 174 
UL26 were amplified by PCR using forward and reverse primers (5’ 175 
GCCGTATGTCCAAGACCTTC 3’) and (5’ CCCACAGGAATAGGTTGTGG 3’), and (5’ 176 
CGGGTCTTTCCCAGCATTAC 3’) and (5’ GTCAACGTCCACGTGTGCT 3’) 177 
respectively, and sequenced directly. Sequence analysis was carried out using 178 
SnapGene software.  179 
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Results and Discussion 180 
Laboratory strains of HSV1 exhibit variable ability to spread via an extracellular 181 
route. A simple phenotypic assessment of HSV1 fitness is its ability to transmit 182 
between cells in culture. The standard method for measuring cell-to-cell spread of 183 
many viruses including HSV1 is to conduct a plaque assay whereby released virus is 184 
inhibited, either physically by the use of a semi-solid overlay such as agarose or CMC, 185 
or immunologically by the inclusion of anti-HSV1 antibodies in the medium overlaying 186 
the cell monolayer, thereby measuring direct transfer between cells in contact with 187 
each other (cell-to-cell spread in Fig. 1A &1B). In our case, we routinely use 1% 188 
pooled human serum to neutralise extracellular virus spread, while allowing cell-to-cell 189 
spread, resulting in the production of a plaque that increases in diameter over time. Of 190 
note, if the same process is carried out without the inclusion of human serum in the 191 
medium, then released virus is free to spread through the extracellular medium, 192 
resulting in the formation of characteristic “comet” shaped plaques at early times and 193 
total destruction of the monolayer at later times (extracellular spread in Fig. 1A & 1B). 194 
Hence the relative size of the comet is an indirect indication of the efficiency of virus 195 
release from infected cells, and it is this assay that forms the basis of the study 196 
presented here.  197 
While carrying out plaque assays for our lab stock of Glasgow strain 17 syn+ (s17) in 198 
parallel to the Sc16 strain, we noted that when human serum was absent from the s17 199 
plaque assays there was little appearance of extracellular spread even at 72h after 200 
infection, in contrast to Sc16 where only two plaque-forming units were sufficient to 201 
completely destroy the monolayer under the conditions of the experiment here (Fig 202 
1C). Moreover, comparison with the KOS strain indicated that extracellular spread was 203 
also a feature of this virus despite it forming smaller plaques overall, suggesting that 204 
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the defect in extracellular release of s17 phenotype was unusual (Fig 2A). To 205 
quantitate the relative virus release from these three strains, BSC1 cells in six well 206 
plates were infected with approximately 30 plaque forming units (PFU) of each strain. 207 
At daily intervals, the extracellular media was harvested and the virus in these 208 
fractions was titrated. The remaining infected BSC1 cells were fixed and stained to 209 
determine the extent of comet tail formation. The stained monolayers confirmed that 210 
while both Sc16 and KOS spread efficiently through the extracellular medium causing 211 
complete destruction by day 3, s17 formed only localised plaques with most of the 212 
monolayer intact at 72 hours (Fig. 2B), with a 1000-fold difference between Sc16 and 213 
s17 release from the cell (Fig. 2C).  214 
To ensure this s17 release phenotype was not specific to BSC1 cells, we titrated Sc16 215 
and s17 on to three other cell types – Vero, SKOV3 and HCT116 cells – in both the 216 
presence and absence of human serum. In all cases, Sc16 spread extracellularly, but 217 
s17 did not (Fig. 3). Moreover, despite the fact that Sc16 formed tiny plaques on 218 
HCT116 cells in the presence of human serum, suggesting that the cell-to-cell spread 219 
route is inefficient in these cells, the monolayer was completely destroyed in the 220 
absence of human serum confirming efficient release and dissemination of Sc16 221 
virions (Fig. 3).  222 
Glasgow Strain17 syn+ contains two release phenotypes. Our s17 virus had been 223 
plaque purified from the original strain 17 syn+ virus stock that we had received from 224 
Glasgow. This raised the possibility that we had selected a particular subtype of the 225 
virus with a different phenotype to the parental virus. Strikingly, comparison of 226 
Glasgow strain 17 syn+ (Gla s17) extracellular spread with Sc16, KOS and s17 227 
indicated that while s17 failed to spread further than the cells surrounding the point of 228 
infection, the parental Gla s17 virus spread as efficiently as Sc16 and KOS, resulting 229 
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in complete destruction of the cell monolayer (Fig 4A). These results indicate a genetic 230 
variation between our lab s17 and its parent virus that results in a dramatic difference 231 
in the ability of the virus to be released from the cell.  232 
Due to the fact we had a number of other recombinant viruses in the lab based on 233 
Glasgow strain 17 syn+, all of which had by definition been plaque purified during 234 
isolation, we next determined the release phenotype of these viruses. This indicated 235 
that three of these viruses failed to form comet tails (Fig. 4B, DUL13, DUL41 and 236 
s17Bac virus), while two were released efficiently (Fig. 4B, DICP0 and D22). Given 237 
that gene deletion could potentially confound the interpretation of these results, we 238 
next plaque purified a further 18 viruses from the parental Glasgow strain 17 syn+ 239 
stock and measured their ability to spread by the extracellular route. As shown in Fig 240 
5, only one of the 18 viruses (virus 7a) that we selected on that occasion failed to 241 
spread extracellularly, confirming that although the phenotype of our original plaque 242 
purified s17 had been re-isolated in this experiment, it represented a relatively minor 243 
fraction of the parental population.  While previous studies have shown that common 244 
lab stocks of HSV1 often comprise a minor population of virus with a fusogenic  245 
phenotype [16], to our knowledge this is the first time that a virus release phenotype 246 
has been identified in this manner. Moreover, given that transgenic s17 also fails to 247 
spread extracellularly, it follows that any viruses built in to this backbone are also likely 248 
to have this release phenotype. 249 
Clinical isolates of HSV1 spread predominantly by cell-to-cell transmission. 250 
Despite the efficient extracellular release phenotype of the available lab strains, it was 251 
not clear if this or the release defective phenotype of s17 would predominate in virus 252 
causing clinical infection. Hence, to assess the spread phenotypes of several 253 
representative clinical HSV1 isolates, we carried out the same extracellular and cell-254 
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to-cell spread assays on nine newly obtained clinical samples of HSV1.  In contrast to 255 
the efficiently released Sc16, there was little evidence of spread by virus release in 256 
any of these clinically isolated viruses (Fig 6). This therefore raises the question of 257 
whether active release of virions from the cell surface is a natural transmission route 258 
for HSV1 in the infected host [28]. Other alphaherpesviruses including varicella zoster 259 
virus and Marek’s disease virus are known to be highly cell-associated in culture [29, 260 
30]. Moreover, clinical isolates of hCMV are initially cell-associated but have been 261 
shown to mutate rapidly in cell culture changing to a virus that is efficiently released 262 
[14]. While some viruses such as influenza virus use neuraminidase in the envelope to 263 
actively promote virion release into the extracellular environment by cleavage of the 264 
glycoprotein attachment site followed by transmission to distal locations [31], other 265 
viruses have evolved to spread mainly by direct cell-to-cell transfer, whereby the virus 266 
particle remains tethered to the cell surface and can only spread into a cell directly in 267 
contact with the infected cell, protecting it from recognition by the immune system. The 268 
classical example of such a virus is HIV, which transmits between T cells via the 269 
virological synapse [32]. Although the molecular detail of HSV1 transmission in the 270 
host is poorly characterized, given the phenotypes of other herpesviruses and our 271 
data presented here, it is possible that commonly used lab strains of HSV1 have 272 
undergone genetic changes that alter a predominantly cell-associated phenotype to 273 
one that, similar to hCMV, becomes more actively released from the cell. However, it 274 
should be noted that recent studies on ten random clinical HSV1 strains isolated in 275 
Finland indicated that while these viruses replicated with lower efficiencies than strain 276 
17 syn+ in all cell types tested, and therefore also released fewer virions,  the overall 277 
proportion of released virus was similar and in some cases higher than strain 17 syn+ 278 
[33]. While the nature of the assays carried out in those studies was different to our 279 
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own (high multiplicity versus spread at low multiplicity respectively), further studies will 280 
be required to determine the relationship between efficient virus release and 281 
propagation in cell culture. Nonetheless, our results suggest that it would be prudent 282 
to combine studies of more clinically relevant HSV1 strains with those of common lab 283 
strains when investigating HSV1 transmission mechanisms. Moreover, given that 284 
HSV1 infects stratified differentiated epithelia in the host, rather than monolayers as 285 
used here, it will be important to determine how the release phenotype affects virus 286 
spread in systems such as organotypic raft culture or human skin explant.  287 
Genome sequencing of strain 17 plaque purified viruses. The above results 288 
indicated that we had isolated two phenotypes from the starting Glasgow strain 17 289 
syn+ virus stock. To determine if we could identify common genetic difference(s) in the 290 
three s17 viruses that fail to release virus efficiently, we carried out second generation 291 
sequencing of seven plaque-purified s17 genomes together with our own lab stock of 292 
the transgenic s17 (s17Bac), totalling four that release virus and three that are 293 
defective. In addition, we sequenced our lab stock of Sc16 genome to compare 294 
relative intrastrain variation to interstrain variation of HSV1 grown in our laboratory. 295 
While sequencing of the Sc16 genome revealed around 800 SNPs of which ~190 296 
were non-synonymous to the strain 17 reference sequence (JN555585.1), in broad 297 
agreement with the published sequence for Sc16 (GenBank KX946970.1) [34], only 298 
around 50 SNPs were found for each of the eight representative strain 17 genomes 299 
that we sequenced, including 6 to 15 non-synonymous changes in each virus (Table 1 300 
& Fig. 7). These statistics are in line with previously published intrastrain sequencing 301 
variations from single virus stocks for three isolates of strain KOS and two isolates of 302 
strain F [16]. Apart from inaccuracies in the repeat regions of the genome, our 303 
transgenic s17 sequence matched that for transgenic strain 17 in Genbank 304 
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(FJ593289.1), confirming that our sequencing pipeline was accurate. Moreover, our 305 
Sc16 sequence revealed ony 4 non-synonymous SNPs compared to the published 306 
sequence [34], despite each sequenced stock being propagated in different 307 
laboratories. Interestingly, of the identified coding changes in the sequenced s17 308 
genomes, only three were present in the three non-spreading viruses – in genes 309 
UL25, UL26 and UL55 – but not in the other five viruses (in bold, Table 1; Fig. 7). 310 
Sanger sequencing of the UL25 and UL26 genes confirmed that those two variations 311 
also segregated appropriately in the D41 and DUL13 viruses which had been isolated 312 
several decades ago in a different laboratory [19, 20], and which as shown above also 313 
failed to spread extracellularly (Fig 4B). Such analyses do not prove that either or both 314 
of these variations are responsible for the defective release phenotype of these 315 
viruses, but it is interesting to note that UL26 encodes a protease which although 316 
characterized to be involved in capsid assembly, may nonetheless has the potential to 317 
have other activities during infection such as facilitating virus release from the cell 318 
surface. Although it has not yet been possible to directly correlate intrastrain genetic 319 
changes with phenotypic changes in these viruses, it should be noted that a recent 320 
study of clinical isolates also failed to identify sequences that would be predictive for 321 
phenotypic differences of virus replication and release [33], suggesting that these 322 
phenotypes are complex and multifactorial. 323 
Hypervariable gC sequences in Glasgow strain 17 syn+. In the course of this 324 
genomic sequencing we identified another frequent S57N variation in the gC open 325 
reading frame, which despite its possible relevance to a virus release phenotype, was 326 
not seen to segregate with either the positive or negative release phenotypes (Table 327 
1). Nonetheless, we also identified a potential single nucleotide deletion at a 328 
homopolymeric run at proline residue 196 in the gC gene of pp3 and pp7a viruses, 329 
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which if correct would result in a frameshift and premature termination at residue 198 330 
of the open reading frame.  This was similar to a previously identified variant of gC in 331 
the genome of the Glasgow strain 17 syn+ - derived ICP0 deletion mutant dl1043 [35], 332 
where a similar single nucleotide deletion at a homopolymeric run at proline 62 333 
followed by termination at 175 was identified [36], suggesting that the gC gene is 334 
susceptible to such variations. We carried out Sanger sequencing of the gC gene from 335 
the 18 plaque-purified viruses denoted in Fig 5. Within these viruses we found the 336 
reference sequence, and another seven variants of gC, including the S57N variation, 337 
five which contained different frameshifts and premature stop codons, and one which 338 
contained a premature stop (Fig 8A). To confirm expression of each of these gC 339 
proteins, we analysed cell lysates from cells infected with these viruses by SDS-PAGE 340 
and Western blotting for gC (Fig 8B). This indicated that all viruses expressed their gC 341 
proteins, and those viruses containing premature stop codons produced significantly 342 
smaller gC peptides. Furthermore, the fact that this monoclonal antibody recognised 343 
every gC variant placed its epitope at the N-terminus of the protein. With the exception 344 
of the shortest molecule, which migrated at only a slightly higher molecular weight 345 
than predicted, the sizes of the other gC molecules were larger than their primary 346 
sequences predicted (Fig 8B), indicating that these gC variants were glycosylated in a 347 
manner supported by previously mapped glycosylation sites (Fig 8A).  Although gC in 348 
pp22a was full-length, it was consistently expressed at a very low level, suggesting 349 
that another indirect mechanism such as mutation of the gene promoter may be 350 
responsible. Further PCR, cloning and sequencing of thirty gC clones from the original 351 
strain 17 virus stock revealed yet another four variants of gC (Table 2).  352 
In total, we have identified 13 variants of gC in the original stock of Glasgow strain 17 353 
syn+, extending a previous study that had already identified one of these [36]. While it 354 
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remains to be determined why our original strain 17 stock contained quite so many gC 355 
variants, we suggest that these variants could be present in many strain 17 derived 356 
viruses dispersed throughout the world. Eight of these variants involve a one 357 
nucleotide frameshift at homopolymeric G/C tracts, resulting in a range of prematurely 358 
terminated proteins that all lack the gC transmembrane domain, producing proteins 359 
that as we have shown above are expressed and in theory would be secreted rather 360 
than incorporated into the virus envelope. A similar frameshift has been reported 361 
before in the macroplaque strain of HSV1 which also fails to express full-length gC 362 
[37]. Splicing of the gC mRNA has also been shown to result in a secreted form of gC 363 
in infected cells due to the lack of a transmembrane domain [38], with the authors of 364 
that study suggesting that this form of secreted gC could act as a virulence factor. Of 365 
note, the varicella zoster virus glycoprotein C has also been shown to be 366 
hypervariable due to strain variation in copy numbers of a repeat sequence within the 367 
gene [39], suggesting that gC variation may be a common alphaherpesvirus trait. 368 
Another example of an HSV1 gene that develops variation due to insertions or 369 
deletions at homopolymeric runs is the thymidine kinase gene, particularly in patients 370 
in response to antiviral treatment with acyclovir [40]. Glycoprotein G has also been 371 
shown to be highly variable, with around 40% of isolates exhibiting genetic variation in 372 
one study [12].  Amongst these variations within gG, homopolymer frameshifts have 373 
been identified in a small number of natural clinical isolates of HSV1 and HSV2 [12, 374 
13]. What is striking about our strain 17 syn+ gC result presented here is that all 13 gC 375 
variations were found in a single aliquot of the original virus stock received from 376 
Glasgow, indicating that it already contained this highly mixed genomic population. 377 
The mechanism of insertion or deletion at such homopolymeric runs is likely to be due 378 
to the HSV1 polymerase slipping or stuttering in a similar manner to that found to 379 
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occur in the mRNA editing mechanism of paramyxovirus RNA polymerases, which 380 
insert a variable number of G residues at a specific homopolymeric run within their P 381 
genes [41]. Given the extent of homopolymeric runs distributed throughout the HSV1 382 
genome [10], it is highly likely that further diversity in these genes will emerge as more 383 
sequences are obtained from isolates obtained from across the globe. In summary, 384 
our results presented here add to the growing understanding of HSV1 genetic 385 
diversity and evolution in both the clinic and the laboratory, and have potential 386 
implications for studies involving strain 17-derived viruses. 387 
 388 
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s17 Ref Gene s17Bac s17 pp3 pp4 pp5 pp8 pp7a pp22a 
3475 RL2     R150H    
3497 RL2    N157K  N157K N157K  
4370 RL2    A403P     
4372 RL2        A404P 
4374 RL2    V405A V405A    
4383 RL2     C408S    
5113 RL2      V651M   
9978 UL1      S214N   
9978 UL2         
10720 UL2        G279D 
11495 UL3      R169*   
12525 UL5      L870I   
14214 UL5   L307M      
20808 UL9 S818N        
24039 UL10 V279M      V279M  
 UL11 E39K   E39K  E39K E39K  
26671 UL12  R73H    R73H R73H  
26865 UL12  C9Y    C9Y C9Y  
26866 UL12 A8V        
27473 UL13 T344I        
36965 UL19 A1189T        
42783 UL21    A237T     
45357 UL22     G343C    
45656 UL22    T243M    T243M 
46927 UL23 R293W      R293W  
47909 UL24     V58I    
48533 UL24   A266T      
49496 UL25 H228R H228R     H228R  
51314 UL26        D169N 
52476 UL26 T556I T556I     T556I  
52476 UL26.5 T250I T250I     T250I  
60496 UL29     A520V    
60874 UL29       A394V  
65210 UL30   L802F      
66850 UL31        A177V 
69041 UL32        A41V 
69646 UL34      G5D   
70353 UL34     R241W    
71581 UL36    E2963A     
72307 UL36       P2721H  
76283 UL36   L1396F  L1396F    
78550 UL36    A640V     
92332 UL41        T102M 
94405 UL42        D432N 
96481 UL44 S57N S57N   S57N S57N  S57N 
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99225 UL46        A577T 
100833 UL46    L41F     
100949 UL46 R3H R3H   R3H    
104378 UL48 T235A        
104966 UL48     A39T    
105735 UL49 L220I        
106334 UL49 E20G        
106750 UL49A        C82Y 
107119 UL50       Q37*  
107228 UL50      A73V   
114857 UL54  R374C       
115516 UL55       T7I  
115918 UL55        C141Y 
115922 UL55 H142Q H142Q     H142Q  
115952 UL55   W152* W152*  W152*   
128783 RS1     P783R    
128786 RS1     Q782G    
128790 RS1     A781I    
128792 RS1     P780Q    
133070 US1      V142F   
133713 US1 DS356G        
134133 US2     E267K    
139897 US7     D37Y    
139903 US7   G39R G39R  G39R   
140564 US7        T259M 
144820 US10      S94N S94N  
144873 US10  N76K       
144873 US11  P127T       
144894 US11                     D120N 
Coding changes 17 11 6 11 18 17 16 14 
Total SNPs 27 22 47 56 61 39 50 55 
 525 
Table 1: Non-synonymous changes in viruses derived from Glasgow strain 17 526 
syn+. Genomic sequences of seven plaque-purified viruses were aligned with the 527 
strain 17 reference sequence (JN555585.1). BAC refers to transgenic strain 17 528 
sequenced from the transgenic strain 17 virus that had been grown in our laboratory. 529 
SNPs shared between the three viruses defective for extracellular release (s17Bac, 530 
s17 and pp7a) are in bold.  531 
 532 
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 533 
 534 
Table 2: Glycoprotein C variants found in Glasgow strain 17 syn+. The gC gene 535 
was sequenced by PCR amplification of 18 plaque purified viruses and 26 clones of 536 
PCR amplified gC DNA from the original strain 17 syn+ virus stock.  537 
  538 
Coding Change Frameshift Length (aa) Plaques (18) Clones (26) 
  511 1 5 
S57N  511 3 3 
S57N/R155L  511 0 1 
 P371 409 0 1 
Q307*  307 1 0 
S57N H202 229 1 0 
 P196 198 4 6 
 G188 198 1 0 
 P122 175 0 1 
S57N P122 175 0 1 
 P88 175 0 1 
S57N P88 175 1 1 
S57N P62 175 6 6 
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Figure Legends 539 
Figure 1: Differential release phenotypes of two laboratory strains of HSV1. (A) 540 
HSV1 can spread by direct cell-to-cell spread or extracellular release followed by 541 
spread to distal cells. Direct spread is assessed by performing plaque assays in the 542 
presence of neutralizing human serum; extracellular spread is assessed by performing 543 
plaque assays in the absence of human serum. (B) Approximately 10 pfu of HSV1 544 
(strain Sc16) was plated on to BSc1 cells and incubated in the presence or absence of 545 
1% human serum to inhibit extracellular virus. (C) Strains Sc16 and s17 were titrated 546 
onto BSc1 cells in the presence (cell-to-cell) or absence (extracellular) of human 547 
serum. Plates were fixed and stained with crystal violet 36 and 72 hours later. 548 
Figure 2: Strain 17 is defective for extracellular release. (A) Strain 17, Sc16 and 549 
KOS strains of HSV1 were titrated on to BSc1 cells in the presence or absence of 550 
human serum and fixed and stained with crystal violet 48 hours later.  (B) & (C) 551 
Approximately 30 plaque forming units of Sc16, KOS or strain 17 virus was used to 552 
infect BSc1 cells grown in a six well plate. At daily intervals the supernatant was 553 
harvested and titrated on to Vero cells (C) and the remaining cells fixed and stained 554 
with crystal violet.  555 
Figure 3: Strain 17 is defective for extracellular release in a range of cell types. 556 
Strain 17 and Sc16 strains of HSV1 were titrated on to Vero, SKOV3 and HCT116 557 
cells in the presence or absence of human serum and fixed and stained with crystal 558 
violet 72 hours later.   559 
Figure 4: The original Glasgow strain 17 syn+ stock contained two extracellular 560 
release phenotypes. (A) BSc1 cells grown in 6-well plates were infected with 561 
approximately 30 plaque forming units of Sc16, KOS, Glasgow strain 17 and plaque 562 
purified s17 in the presence or absence of human serum. Cells were fixed at 72 hours 563 
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and stained with crystal violet. (B) As in A, but cells were infected with strain 17-564 
derived viruses as denoted.  565 
Figure 5: Extracellular release phenotypes of multiple plaque purified Glasgow 566 
strain 17 isolates. Eighteen plaques were purified from Glasgow strain 17 syn+ virus, 567 
and approximately 10 plaque forming units of each was plated onto BSc1 cells grown 568 
in 6-well plates in the absence of human serum. The cells were fixed after 72 hours 569 
and stained with crystal violet.  570 
Figure 6: Clinical isolates of HSV1 exhibit defective extracellular release. Nine 571 
clinical isolates were plated onto BSc1 cells grown in 6-well plates in the absence or 572 
presence of human serum, alongside Sc16. The cells were fixed after 72 hours and 573 
stained with crystal violet.  574 
Figure 7: Single nucleotide polymorphisms (SNPs) in seven strain 17 syn+ 575 
derived isolates. The HSV-1 genome is represented in yellow with ORFs arrayed 576 
above and below (dark grey) according to strand.  Each light grey band indicates a 577 
different sequenced genome, track order (out to in) is 578 
s17>s17Bac>pp7a>pp3>pp4>pp5>pp8>pp22a.  Red indicates non-synonymous 579 
SNPs and black indicates non-coding or synonymous SNPs. Coding SNPs common to 580 
the three release defective viruses (s17, s17Bac and pp7a) are shown in blue, as are 581 
the ORFs in which they are located (UL25, UL26 and UL55). The gC ORF (UL44) has 582 
also been highlighted in blue (also see Fig 8). 583 
Figure 8: Glasgow strain 17 syn+ contains multiple variants of glycoprotein C. 584 
(A) Eight variants of gC were identified in the strain 17 plaques shown in Fig 5, 585 
including the original reference sequence.  Six of these contained frameshifts at 586 
homopolymeric runs resulting in proteins truncated at premature stop codons. 587 
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Diamonds denote known glycosylation sites. The predicted and actual molecular 588 
weight of these molecules (as identified in B) are shown on the right-hand side. (B) 589 
BSc1 cells infected with the denoted viruses were harvested at 18 hours and analysed 590 
by SDS-PAGE on a 13% polyacrylamide gel followed by Western blotting for gC, 591 
VP16 and a-tubulin. Molecular weight markers are shown on right-hand side in kDa.  592 
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